Biotechnology News and Research RSS Feed - Biotechnology News and Research

CardioNova initiates Phase 1b clinical trial with AtheroNova's AHRO-001

CardioNova initiates Phase 1b clinical trial with AtheroNova's AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001. [More]
Do we take liquid calories into account when planning meals?

Do we take liquid calories into account when planning meals?

New research by academics in the University of Bristol's Nutrition and Behaviour Unit (NBU) has looked into whether we take liquid calories into account when planning meals. [More]
Cloud Pharmaceuticals awarded Phase I grant from NSF SBIR program

Cloud Pharmaceuticals awarded Phase I grant from NSF SBIR program

Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it has been awarded a Phase I grant from the National Science Foundation Small Business Innovation Research program. [More]
FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

FDA clears Lorus' LOR-253 IND application for treatment of hematologic malignancies

Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma. [More]
Nicotine, cotinine can potentially inhibit DNA damage caused by NNK in tobacco smoke

Nicotine, cotinine can potentially inhibit DNA damage caused by NNK in tobacco smoke

A new in vitro study has revealed that nicotine and cotinine, a metabolite of nicotine, can potentially inhibit DNA damage caused by a certain carcinogen in smoke. [More]
Amgen declares share dividend for third quarter 2014

Amgen declares share dividend for third quarter 2014

Amgen announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. [More]
Genticel provides update on patents granted in the USA and Asia

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate. [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
AMSBIO-Trevigen prize winner announced

AMSBIO-Trevigen prize winner announced

AMSBIO, regular sponsor of the annual Beatson International Cancer Conference announces that the winner of the AMSBIO-Trevigen prize for the best poster was Katarzyna Grzes - a PhD researcher specialising in Cell Signaling and Immunology at the University of Dundee (Scotland, UK).
Miss Grzes was named as winner of the Poster Prize for the best presented and most interesting poster for her work entitled 'Metabolic regulation in PTEN null T lymphoma / leukemia'. [More]

TransCelerate selects Cognizant to develop first-of-its-kind, subscription-based platform

Cognizant today announced that it has been selected by TransCelerate BioPharma Inc., a non-profit organization with membership representation from 19 major pharmaceutical companies, to develop a first-of-its-kind, subscription-based platform that will transform the way clinical sites collaborate with pharmaceutical companies on clinical trials. [More]
Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire, ArmaGen partner to develop AGT-182 drug for treatment of Hunter syndrome

Shire plc, the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome (MPS II). [More]
Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. [More]
Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). [More]
New discovery links two important hypotheses in Alzheimer's disease research

New discovery links two important hypotheses in Alzheimer's disease research

In Alzheimer's disease, accumulation of amyloid plaque in the brain is believed to play an important role in many characteristic disease symptoms, including memory loss and other mental state changes. [More]
Researchers propose ‘microbiome cloud model’ to understand variation in individual's microbiome composition

Researchers propose ‘microbiome cloud model’ to understand variation in individual's microbiome composition

The Human Microbiome Project (HMP) is a global initiative to identify and characterize the microorganisms present at multiple sites in the human body. [More]
Researchers develop new single-cell technique to study environmental effects on DNA

Researchers develop new single-cell technique to study environmental effects on DNA

Researchers at the BBSRC-funded Babraham Institute, in collaboration with the Wellcome Trust Sanger Institute Single Cell Genomics Centre, have developed a powerful new single-cell technique to help investigate how the environment affects our development and the traits we inherit from our parents. [More]
Study illustrates how domino effect of one genetic error can contribute to hydrocephalus

Study illustrates how domino effect of one genetic error can contribute to hydrocephalus

The mysterious condition once known as "water on the brain" became just a bit less murky this week thanks to a global research group led in part by a Case Western Reserve researcher. [More]
Signaling pathway key player in formation of front-most portion of developing vertebrate embryos

Signaling pathway key player in formation of front-most portion of developing vertebrate embryos

A signaling pathway once thought to have little if any role during embryogenesis is a key player in the formation of the front-most portion of developing vertebrate embryos. [More]
Splice-switching oligonucleotide drugs alter editing of gene transcript

Splice-switching oligonucleotide drugs alter editing of gene transcript

In splice-switching, an innovative therapeutic approach, targeted oligonucleotide drugs alter the editing of a gene transcript to produce the desired form of a protein. [More]

New article describes about crowdsourcing and drug repurposing needs

Experimental drugs proven safe but perhaps not sufficiently effective in initial testing or against a first disease target may sit gathering dust on the shelves of pharmaceutical companies. [More]